POTELIGEO is a CCR4-targeted
monoclonal antibody

POTELIGEO is a humanized monoclonal antibody (mAb) that selectively targets and binds to CCR4-positive malignant T-cells, mediating the process of antibody-dependent cellular cytotoxicity (ADCC).1,13 Through this process, POTELIGEO activates immune effector cells (natural killer cells and monocytes) triggering the release of cytotoxic molecules that kill CCR4-positive malignant T-cells.1

POTELIGEO was developed with proprietary POTELLIGENT® technology that enhances ADCC by removing fucose from the mAb’s Fc receptor region through a process called defucosylation.1,14 Defucosylation increases binding affinity to effector cells, which may increase ADCC activity by up to 100-fold compared with conventionally fucosylated mAbs.14-18

View the mechanism of action of POTELIGEO

POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Important Safety Information